We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Arena Pharma, Investors Strike $24M Deal In Diet Drug Suit

Law360, New York (November 8, 2017, 4:42 PM EST) -- Arena Pharmaceuticals Inc. has reached a $24 million cash-and-stock deal with a proposed class of investors to settle its seven-year battle in California federal court over allegations the company lied to shareholders that testing was going smoothly for its diet drug lorcaserin, which is sold under the trade name Belviq.

Lead plaintiff Carl Schwartz asked U.S. District Judge Cathy Ann Bencivengo on Tuesday to grant preliminary approval to the deal, which would see investors drop their claims against Arena in exchange for its payment of a...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Schueneman v. Arena Pharmaceuticals, Inc. et al


Case Number

3:10-cv-01959

Court

California Southern

Nature of Suit

Securities/Commodities

Judge

Cathy Ann Bencivengo

Date Filed

September 20, 2010

Law Firms

Companies

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.